Find, compare & contact
Vildagliptin
API Manufacturers & Suppliers
Filters
Reset current filters
Type
Production region
Qualifications
Country of origin
Producer
Produced in:
Established in: 1972
MOQ: -
Employees: 1,000+
EU-GMP for APIs and CEP for certain APIs
Exporting to over 50 countries worldwide
Long-standing technological advantage in adamantane, quinuclidine and nitrofurane chemistry
+ 0
All certificates
Producer
Produced in:
Established in: 1978
MOQ: -
Employees: 10k+
199 API-Related Granted Patents
Global Presence in 50+ Markets
Advanced technology and R&D Capabilities
+ 0
All certificates
Producer
Produced in:
Established in: 2011
MOQ: 100 g
Employees: 10+
Fast Response and Good Communication
Willingness To Start From Small
Flexible Payment Terms
+ 0
All certificates
Distributor
Produced in:
Established in: 1987
MOQ: 100 g
Employees: 50+
ISO 9001:2015 & SGS audited supplier
One-stop CDMO Solutions for APl and Key intermediates
Specialized in APIs & Pharmaceutical Intermediates for 37 years
+ 0
All certificates
Producer
Produced in:
Established in: 2021
MOQ: -
Employees: 19
API, Intermediates, Building Blocks, Impurities, Amino acids and Peptides
Small quantity APIs to commercial scale
GMP and USFDA certification based on quantity, order, assignment.
+ 0
All certificates
Distributor
Produced in:
Established in: 1997
MOQ: -
Employees: 50
GMP and GDP certified
Biotechnological research leadership and manufacturer
Extensive distribution network for product global accessibility
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
Produced in:
Established in: 1995
MOQ: -
Employees: 10000
Fermentation technology Experts
Partnerships with 1200 pharma companies in 100+ countries
US FDA, EMA, COFEPRIES, ANVISA, PMDA accreditations
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Vildagliptin API 274901-16-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Vildagliptin. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Vildagliptin
- Synonyms:
- Galvus , EQUA , Jalra , LAF 237 , Vildagliptin , Xiliarx
- Cas Number:
- 274901-16-5
- DrugBank number:
- DB04876
- Unique Ingredient Identifier:
- I6B4B2U96P
About Vildagliptin
Here you will find more information about Vildagliptin. Vildagliptin, previously identified as LAF237, is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vidagliptin subsequently acts by inhibiting the inactivation of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) by DPP-4. This inhibitory activity ultimately results in a two-fold action where GLP-1 and GIP are present to potentiate the secretion of insulin by beta cells and suppress glucagon secretion by alpha cells in the islets of Langerhans in the pancreas.
It is currently in clinical trials in the USA and has been shown to reduce hyperglycemia in type 2 diabetes mellitus. While the drug is still not approved for use in the US, it was approved in Feb 2008 by European Medicines Agency for use within the EU and is listed on the Australian PBS with certain restrictions.
You can ask the supplier about all relevant certificates for the product such as CoA, Safety Data Sheet and DMF.
Vildagliptin is a type of DPP4-Inhibitors
DPP4-Inhibitors, or dipeptidyl peptidase-4 inhibitors, belong to the subcategory of pharmaceutical active ingredients known for their therapeutic role in managing type 2 diabetes mellitus. These inhibitors work by targeting and inhibiting the action of the enzyme dipeptidyl peptidase-4 (DPP4) in the body.
DPP4 is responsible for breaking down incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP4, DPP4-Inhibitors enhance the levels and activity of these hormones. GLP-1 and GIP play crucial roles in regulating blood sugar levels by stimulating insulin release, inhibiting glucagon secretion, and slowing down gastric emptying.
The main advantage of DPP4-Inhibitors is their ability to improve glycemic control without the risk of hypoglycemia, which is a common side effect of some other diabetes medications. They are typically used as an adjunct therapy in combination with other antidiabetic agents, such as metformin, to achieve optimal glucose management.
Commonly prescribed DPP4-Inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin. These drugs are available in oral tablet formulations, allowing for convenient administration. They have shown efficacy in lowering HbA1c levels and have a favorable safety profile.
It is important to note that DPP4-Inhibitors are not suitable for individuals with type 1 diabetes or those with a history of pancreatitis. As with any medication, there may be potential side effects, such as upper respiratory tract infections, headache, and gastrointestinal discomfort, which should be discussed with a healthcare professional.
In conclusion, DPP4-Inhibitors are a subcategory of pharmaceutical APIs that act by inhibiting the enzyme DPP4, thereby enhancing the effects of incretin hormones involved in glucose regulation. They are widely used in the management of type 2 diabetes mellitus, offering glycemic control benefits with a reduced risk of hypoglycemia.
Vildagliptin (DPP4-Inhibitors), classified under Anti-diabetics
Anti-diabetics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are a group of compounds designed to manage and treat diabetes mellitus, a chronic metabolic disorder characterized by high blood sugar levels. These medications play a vital role in controlling diabetes and preventing complications associated with the disease.
Anti-diabetics encompass a wide range of drug classes, including biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Each class works through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.
Biguanides, such as metformin, reduce glucose production by the liver and enhance insulin sensitivity in peripheral tissues. Sulfonylureas, like glipizide, stimulate insulin secretion from pancreatic beta cells. Thiazolidinediones, including pioglitazone, improve insulin sensitivity in muscle and adipose tissues. DPP-4 inhibitors, such as sitagliptin, increase insulin release and inhibit glucagon secretion. SGLT2 inhibitors, like dapagliflozin, decrease renal glucose reabsorption, leading to increased urinary glucose excretion. GLP-1 receptor agonists, such as exenatide, enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.
These anti-diabetic APIs serve as the foundational ingredients for the formulation of various oral tablets, capsules, and injectable medications used in the treatment of diabetes. By targeting different aspects of glucose regulation, they help patients achieve and maintain optimal blood sugar levels, thus reducing the risk of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.
It is crucial for healthcare professionals to prescribe and administer these anti-diabetic medications appropriately, considering factors like the patient's medical history, co-existing conditions, and potential drug interactions. Regular monitoring of blood glucose levels and close medical supervision are necessary to ensure effective diabetes management.
In conclusion, anti-diabetics form a critical category of pharmaceutical APIs used for the treatment of diabetes. These compounds, encompassing various drug classes, work through distinct mechanisms to regulate blood sugar levels and improve insulin sensitivity. By facilitating glucose control, anti-diabetic APIs help mitigate the risk of complications associated with diabetes mellitus, ultimately promoting better health outcomes for patients.
Vildagliptin manufacturers | traders | suppliers
We have 20 companies offering Vildagliptin produced in 9 different countries.
Get in contact with the supplier of your choice:
- Olpha from Latvia, product country of origin Latvia
- Jubilant Pharmova from India, product country of origin India
- Shandong Octagon Chemicals Limited from China, product country of origin China
- Sinoway industrial Co.,Ltd from China, product country of origin China
- SETV Global from India, product country of origin India
- AXXO GmbH from Germany, product country of origin World
- Lee Pharma from India, product country of origin India
- Menovo from China, product country of origin China
- Cambrex from Italy, product country of origin United States
- Biocon from India, product country of origin India
- Hikal from India, product country of origin India
- Beijing Huikang Boyuan from China, product country of origin China
- Tianjin Minxiang from China, product country of origin China
- Fuxing Long Rui Pharma from China, product country of origin China
- KRKA from Slovenia, product country of origin Slovenia
- Gedeon Richter from Hungary, product country of origin Hungary
- Honour Lab from India, product country of origin India
- Medichem from Spain, product country of origin Malta
- MSN Pharma from India, product country of origin India
- Moehs from Spain, product country of origin Spain
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.